Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 5/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.52 |
| ▸ | AURKA | O14965 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339944 | 0.92 | IKBKB (0.51) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5341896 | 0.92 | IKBKB (0.51) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5338761 | 0.89 | IKBKB (0.52) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5337161 | 0.88 | IKBKB (0.52) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5337556 | 0.88 | IKBKB (0.51) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5334121 | 0.86 | IKBKB (0.54) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5333595 | 0.86 | IKBKB (0.55) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5340154 | 0.86 | IKBKB (0.59) | IKBKBCCNA2CDK2CCNA1 | |
| SCHEMBL5337719 | 0.85 | IKBKB (0.53) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5337322 | 0.84 | IKBKB (0.51) | IKBKBCCNA2CDK2CCNA1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | claimed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | claimed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | IKBKB 55/4885CCNA2 2589/4885CDK2 392/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | IKBKB 55/4885CCNA2 2589/4885CDK2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.